Female Infertility Market Growth Anticipated by 2032 | Major Players: Ferring Pharmaceuticals, Instituto Valenciano de Infertilidad, IVI Alicante/ Merck, S.L., Spain, expected to boost the market

In the market landscape of Female Infertility, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled  “Female Infertility Market Insights, Epidemiology and Market Forecast 2032” from DelveInsight. 

The Female Infertility market report sheds light on Female Infertility current treatment practices, upcoming drugs in the Female Infertility pipeline, market shares of individual therapies, and the anticipated trajectory of the Female Infertility market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Female Infertility Market Growth

The market size shall grow during the forecast period, i.e., 2023–2032 owing to the increasing prevalence of Female Infertility. The market size is expected to increase during the study period.

Discover the Anticipated Evolution and Growth of the Market @ Female Infertility Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

• Female Infertility Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Ferring Pharmaceuticals, Instituto Valenciano de Infertilidad, IVI Alicante/ Merck, S.L., Spain, and others, are actively engaged in developing novel drugs for potential market entry.
• Female Infertility Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Female Infertility. Therapies such as Menopur® Pen, Pre-treatment with rLH (Luveris 75 IU), and others are driving the Female Infertility market.

Female Infertility Treatment Market

Infertility treatment depends on the cause, age, how long the women has been infertile and personal preferences.Because infertility is a complex disorder, treatment involves significant financial, physical, psychological and timecommitments. Although some women need just one or two therapies to restore fertility, it's possible that severaldifferent types of treatment may be needed. Treatments can either attempt to restore fertility throughmedicationor surgery, or help get pregnant with sophisticated techniques.

Restoration of the fertility in women can be done in the following ways: 

• By stimulating ovulation with fertility drugs: Fertility drugs regulate or stimulate ovulation. Fertility drugs arethe main treatment for women who are infertile due to ovulation disorders. Some of them are: 

• Clomiphene citrate

• Gonadotropins

• Metformin

• Letrozole

• Bromocriptine, etc. 

• By Surgery: Several surgical procedures can correct problems or otherwise improve female fertility. However,surgical treatments for fertility are rare these days due to the success of other treatments. They include:

• Laparoscopic or hysteroscopic surgery

• Tubal surgeries

• Assistive Reproductive Technology (ART) for the infertile females include: 

• Intrauterine Insemination (IUI) 

• Assisted Reproductive Technology: IVF is the most effective assisted reproductive technology. An IVF cycle takes several weeks and requires frequent blood tests and daily hormone injections.If women have ovulation problems, they may be prescribed drugs such as clomiphene citrate (Clomid, Serophene),gonadotropins (such as Gonal-F, Follistim, Humegon and Pregnyl), or letrozole. Gonadotropinscan triggerovulation when Clomid or Serophene don't work. These drugs also can also help you get pregnant by causing theovaries to release multiple eggs. Normally, only one egg is released each month. The doctors may suggest that totake gonadotropin if one have unexplained infertility or when other kinds of treatment haven't helped in gettingpregnant. Metformin (Glucophage) is another type of medication that may help ovulate normally if onehave insulin resistance or PCOS (polycystic ovarian syndrome).

Laparoscopic or hysteroscopic surgeries can remove or correct abnormalities to help improve the chances of getting pregnant. Surgery might involve correcting an abnormal uterine shape, removing endometrial polyps and some types of fibroids that misshape the uterine cavity, or removing pelvic or uterine adhesions.

Female Infertility Treatment Market

The dynamics of Female Infertility market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2023–2032. 

Luveris is recommended for the treatment of adult women who have been shown to produce very low levels of some of the hormones involved in the natural reproductive cycle. The medicine is used together with another hormone called Follicle Stimulating Hormone, (FSH), to bring about the development of follicles, which are in the ovary, the structures maturing the eggs (ova). It is followed by treatment with a single dose of human Chorionic Gonadotropin (hCG), which leads to the release of an egg from the follicle (ovulation). The present study aims to evaluate the effect of the treatment with LH prior to Controlled ovarian stimulation (COS) on the ovarian response in patients with Poor Ovarian Response (POR) and advanced maternal age, the worst prognosis but more frequent group of poor responders attending fertility clinics. 

Menopur® (menotropins for injection), administered subcutaneously, is indicated for the development of multiple follicles and pregnancy in ovulatory patients participating in an Assisted Reproductive Technology (ART) program. Ferring Pharmaceuticals is conducting a Phase III randomized, double-blind double-dummy trial comparing menopur solution for injection in a pre-filled pen and menopur powder and solvent for solution for injection (menotropins for injection) in a gnrh agonist cycle in women aged 18-42 years undergoing an assisted reproductive technology program.

Female Infertility Market Report Features

Geography Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Study Period: 2019-2032

Female Infertility Market Size: USD XX million in 2032

Key Female Infertility Companies: Ferring Pharmaceuticals, Instituto Valenciano de Infertilidad, IVI Alicante/ Merck, S.L., Spain, and others.

Leading Female Infertility Companies and Emerging Drugs: Pioneering companies such as Ferring Pharmaceuticals, Instituto Valenciano de Infertilidad, IVI Alicante/ Merck, S.L., Spain, among others, are actively developing novel drugs for potential entry into the Female Infertility market.

Female Infertility Therapeutic Landscape: Key therapies identified for Female Infertility treatment include Menopur® Pen, Pre-treatment with rLH (Luveris 75 IU), and more.

Female Infertility Overview:

Female infertility refers to the inability of a woman to conceive or carry a pregnancy to full term after a year or more of regular, unprotected sexual intercourse. There can be various factors contributing to female infertility, which can involve issues with ovulation, fallopian tubes, uterus, or hormonal imbalances.

Here are some common causes and factors associated with female infertility:

• Ovulation Disorders: Irregular or absent ovulation is a significant cause of infertility. Conditions such as polycystic ovary syndrome (PCOS), hypothalamic dysfunction, premature ovarian failure, or issues related to the thyroid gland can affect ovulation.
• Fallopian Tube Damage or Blockage: Damage or blockage of the fallopian tubes can prevent the egg from meeting the sperm, resulting in infertility. This damage can be due to pelvic inflammatory disease (PID), endometriosis, or previous surgeries.
• Uterine or Cervical Problems: Abnormalities in the uterus or cervix, such as polyps, fibroids, or cervical stenosis, can interfere with implantation or prevent the sperm from reaching the egg.
• Age: As women age, their fertility declines due to a decrease in the number and quality of eggs. Fertility starts to decline significantly after the age of 35, with a sharper decline after 40.
• Hormonal Imbalances: Hormonal imbalances, including thyroid disorders, high levels of prolactin, or abnormalities in other hormones that regulate reproductive functions, can affect fertility.
• Lifestyle Factors: Factors such as excessive stress, poor nutrition, excessive exercise leading to very low body fat, smoking, alcohol consumption, and exposure to environmental toxins can negatively impact fertility.

Diagnosis of female infertility involves a comprehensive evaluation by a healthcare professional specializing in reproductive health. This often includes medical history, physical exams, hormonal tests, imaging studies, and sometimes procedures like hysterosalpingography (HSG) or laparoscopy to assess the reproductive organs.

Treatment for female infertility depends on the underlying cause and may include:

• Medications to induce ovulation or regulate hormones.
• Surgical interventions to address issues such as fibroids or blocked fallopian tubes.
• Assisted reproductive technologies (ART) like in vitro fertilization (IVF), intrauterine insemination (IUI), or donor eggs.

Key Facts Female Infertility Market Report:

• Key players such as Ferring Pharmaceuticals, Instituto Valenciano de Infertilidad, IVI Alicante/ Merck, S.L., Spain, and others are investigating its candidates for Female Infertility.
• Female Infertility pipeline includes the major therapies such as Menopur® Pen, Pre-treatment with rLH (Luveris 75 IU), and others. 
• The infertile patients with PCOS had statistically higher occurrence of annovulatory cycle witholigomenorrhoea, hirsutism and serum testosterone levels compared to infertile women with normalovaries. 
• As per the WHO data, the estimated prevalence of primary infertility among reproductive age groupwomen in Asian countries is 11.8%. Global infertility prevalence rates are difficult to determine, due tothe presence of both male and female factors which complicate any estimate which may only addressthe woman and an outcome of a pregnancy diagnosis or live birth.

Female Infertility Epidemiology Segmentation:

About 15-20% women who intend to become pregnant are infertile.

• The fertility decline in female already starts around 25-30 years of age and the median age at last birth is 40-41 years in most studied populations experiencing natural fertility. According to theNational Survey of Family Growth (NSFG) data, 15.5% of all women who intend to become pregnant are infertile (unable to conceive after 1 year of trying) and 6.7% of married women aged 15 to 44 years are infertile.
• About 10 percent of women (6.1 million) in the United States ages 15-44 have difficulty getting pregnant or staying pregnant, according to the Centers for Disease Control and Prevention (CDC).

The Female Infertility market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Female Infertility

• Prevalent Cases of Female Infertility by severity

• Gender-specific Prevalence of Female Infertility

• Type-specific Prevalence of Female Infertility

• Age-specific Prevalence of Female Infertility

• Diagnosed Cases of Female Infertility

DelveInsight's comprehensive report provides a thorough exploration of the Female Infertility market, covering key Female Infertility players, emerging Female Infertility therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Female Infertility Market Outlook 2032

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Female Infertility market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the Female Infertility market, including the competitive environment, key companies developing drugs for Female Infertility , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing tretment practices can helps in identifying gaps and opportunities within the Female Infertility market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Female Infertility. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Female Infertility market with clarity and purpose.

Related Reports:

Female Infertility Epidemiology Forecast

Female Infertility Epidemiology Forecast report delivers an in-depth understanding of the Female Infertility, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Female Infertility Pipeline Insight

Female Infertility Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Female Infertility pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 

Healthcare Consulting and Market Research Services by DelveInsight

Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European biosimilar landscape. Download Pharma Go-to-Market Case Study.

Trending Reports by DelveInsight

Functional Constipation Market

https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Market

https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market

https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market

https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market

https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market

https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market

https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market

https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market

https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market

https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market

https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market

https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market

https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market

https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market

https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market

https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market

https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market

https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market

https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market

https://www.delveinsight.com/report-store/orthotic-devices-market

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Connect with DelveInsight:

LinkedIn | Facebook | Twitter

Contact Us:

Kritika Rehani

Team Lead, Marketing

krehani@delveinsight.com

+91-9650213330

www.delveinsight.com